Premium
Paclitaxel‐Loaded Iron Oxide Nanoparticles for Targeted Breast Cancer Therapy
Author(s) -
Jeon Mike,
Lin Guanyou,
Stephen Zachary R.,
Kato Frances L.,
Zhang Miqin
Publication year - 2019
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.201900081
Subject(s) - paclitaxel , polyethylene glycol , breast cancer , cytotoxicity , chemistry , nanoparticle , drug , cancer cell , solubility , cancer , pharmacology , biophysics , cancer research , nanotechnology , materials science , biochemistry , in vitro , medicine , organic chemistry , biology
Paclitaxel (PTX) is a potent drug for treating advanced solid carcinomas; however, its clinical utility is limited by its poor water solubility. Despite the promise of using nanoparticles to deliver hydrophobic PTX, achieving sufficient drug loading while maintaining small particle size and stability in biological media remains a challenge. Here, a PTX nanoparticle (NP) formulation with small size and great stability is presented that targets breast cancer cells and enables controlled release of PTX. This NP formulation (NP‐PTX‐FA) comprises a superparamagnetic iron oxide core coated with short‐ and long‐chain polyethylene glycol: the former for conjugation of hydrophobic PTX and folic acid (FA), and the latter as an outer layer for improved hydrophilicity. The NP‐PTX‐FA has a uniform size distribution (averaging 28.2 ± 0.64 nm) and high drug loading capacity of 22.8 wt% (vs <10 wt% normally). NP‐PTX‐FA releases the drug under conditions mimicking the acidic intracellular pH of breast cancer cells and the FA conjugation leads to higher NP uptake by target cells, enhancing the cytotoxicity to target cells compared to free PTX. This NP formulation holds great promise to improve breast cancer therapy and potential to deliver other hydrophobic drugs for treating various cancer types.